Efficacy of PD-1 inhibitors in relapsed/refractory classic Hodgkin lymphoma
| Author, year . | Study design . | Treatment setting . | Number of patients . | Key efficacy data . | Key toxicity data . |
|---|---|---|---|---|---|
| Moskowitz et al 202117 Moskowitz et al 202218 | Pembrolizumab-GVD × 2-4 cycles, followed by ASCT | ASCT eligible | 39 | ORR 100%, CR 95% 30-month PFS 96% | Grade ≥3 hepatoxicity 10%; grade ≥3 neutropenia 10% |
| Mei et al 202222 | Nivo × 3, Nivo × 3 and/or Nivo-ICE × 2, then ASCT | ASCT eligible | 43 | Nivo alone: ORR 89%, CR 78%, 2-year PFS 96% Nivo-ICE: ORR 100%, CR 89%, 2-year PFS 86% | 1 case of grade 4 encephalitis; 1 case of grade 3 colitis |
| Bryan et al 202320 | Pembrolizumab-ICE × 2, pembro × 1 | ASCT eligible | 42 | ORR 97.3%, CR 86.5%, 2-year PFS 87.2% | Grade ≥3 hepatoxicity 5%; grade ≥3 neutropenia 36%; 2 grade 5 events |
| Advani et al 202116 | BV+nivolumab | ASCT eligible | 93 | ORR 85%, CR 67%, 3-year PFS 77% | Grade ≥3 pneumonitis 3%, grade ≥3 rash 1%, grade ≥3 AST elevation 1%, Guillain-Barre syndrome 1% |
| Ding et al 202328 | Tislelizumab+GemOx × 6-8, followed by tislelizumab maintenance | Relapsed/refractory; majority without prior ASCT | 30 | ORR 100%, CR 96.7%, 12-month PFS 86% | Grade ≥3 neutropenia 3%, grade ≥3 transaminase elevation 3% |
| Kuruvilla et al 202132 | BV vs pembrolizumab | After prior ASCT or ineligible for ASCT | 153 | Median PFS 13.2 vs 8.3 mos | Grade ≥3 pneumonitis 4% (1 grade 5 event); grade ≥3 neutropenia 2% |
| Chen et al 201938 Armand et al 202329 | KEYNOTE-087: pembrolizumab every 3 weeks up to 2 years | After prior ASCT/BV or salvage chemo/BV or ASCT | 210 | ORR 71.4%, median DOR 16.6 mos, median PFS 13.7 mos, median OS NR, 5-year OS 70.7% | Grade ≥3 neutropenia 2.4%; grade ≥3 pericarditis 1%; grade ≥3 diarrhea 1% |
| Ansell et al 202330 Armand et al 201839 | CheckMate 205: Nivo every 2 weeks until progression or unacceptable toxicity | After prior BV or ASCT or ASCT/BV | 243 | ORR 71.2%, median DOR 18.2 mos, median PFS 15.1 mos, median OS NR, 5-year OS 71.4% | Grade ≥3 hepatitis 4.9%; grade ≥3 colitis 2.1%; grade ≥3 pneumonitis 0.8% |
| Author, year . | Study design . | Treatment setting . | Number of patients . | Key efficacy data . | Key toxicity data . |
|---|---|---|---|---|---|
| Moskowitz et al 202117 Moskowitz et al 202218 | Pembrolizumab-GVD × 2-4 cycles, followed by ASCT | ASCT eligible | 39 | ORR 100%, CR 95% 30-month PFS 96% | Grade ≥3 hepatoxicity 10%; grade ≥3 neutropenia 10% |
| Mei et al 202222 | Nivo × 3, Nivo × 3 and/or Nivo-ICE × 2, then ASCT | ASCT eligible | 43 | Nivo alone: ORR 89%, CR 78%, 2-year PFS 96% Nivo-ICE: ORR 100%, CR 89%, 2-year PFS 86% | 1 case of grade 4 encephalitis; 1 case of grade 3 colitis |
| Bryan et al 202320 | Pembrolizumab-ICE × 2, pembro × 1 | ASCT eligible | 42 | ORR 97.3%, CR 86.5%, 2-year PFS 87.2% | Grade ≥3 hepatoxicity 5%; grade ≥3 neutropenia 36%; 2 grade 5 events |
| Advani et al 202116 | BV+nivolumab | ASCT eligible | 93 | ORR 85%, CR 67%, 3-year PFS 77% | Grade ≥3 pneumonitis 3%, grade ≥3 rash 1%, grade ≥3 AST elevation 1%, Guillain-Barre syndrome 1% |
| Ding et al 202328 | Tislelizumab+GemOx × 6-8, followed by tislelizumab maintenance | Relapsed/refractory; majority without prior ASCT | 30 | ORR 100%, CR 96.7%, 12-month PFS 86% | Grade ≥3 neutropenia 3%, grade ≥3 transaminase elevation 3% |
| Kuruvilla et al 202132 | BV vs pembrolizumab | After prior ASCT or ineligible for ASCT | 153 | Median PFS 13.2 vs 8.3 mos | Grade ≥3 pneumonitis 4% (1 grade 5 event); grade ≥3 neutropenia 2% |
| Chen et al 201938 Armand et al 202329 | KEYNOTE-087: pembrolizumab every 3 weeks up to 2 years | After prior ASCT/BV or salvage chemo/BV or ASCT | 210 | ORR 71.4%, median DOR 16.6 mos, median PFS 13.7 mos, median OS NR, 5-year OS 70.7% | Grade ≥3 neutropenia 2.4%; grade ≥3 pericarditis 1%; grade ≥3 diarrhea 1% |
| Ansell et al 202330 Armand et al 201839 | CheckMate 205: Nivo every 2 weeks until progression or unacceptable toxicity | After prior BV or ASCT or ASCT/BV | 243 | ORR 71.2%, median DOR 18.2 mos, median PFS 15.1 mos, median OS NR, 5-year OS 71.4% | Grade ≥3 hepatitis 4.9%; grade ≥3 colitis 2.1%; grade ≥3 pneumonitis 0.8% |
ASCT, autologous stem cell transplant; AST, aspartate aminotransferase; BV, brentuximab vedotin; CR, complete response; DOR, duration of response; GemOx, gemcitabine, oxaliplatin; GVD, gemcitabine, vinorelbine, liposomal doxorubicin; ICE, ifosfamide, carboplatin, etoposide; mos, months; NR, not reached; ORR, objective response rate; PFS, progression-free survival.